Asian markets fall after Wall Street’s latest record
Stocks retreat in Tokyo, Hong Kong
Stocks retreat in Tokyo, Hong Kong
Tesla’s debt ‘essentially zero,’ S&P says
University of Florida (UF) spinout Atsena Therapeutics has closed a $55 million financing that will help take its gene therapy for a common cause of blindness in children into pivotal trials.
GlaxoSmithKline is stumping up $85 million upfront and up to an extra $730 million in biobucks for Surface Oncology’s early-stage antibody asset.
Three years after coming of out stealth, Vivace Therapeutics has raised another $30 million to pursue drugs targeting the Hippo-YAP pathway. The funding, drawn from Boxer Capital, RA Capital Management and Canaan Partners, will push its lead program into the clinic in the first half of 2021.
Human cells need structures called mitochondria to generate energy for their biochemical activities—and cancer cells are no exception. Researchers at the Karolinska Institutet in Sweden figured that crippling these little power plants could be a strategy for treating cancer.
Novartis teamed up with Cadent Therapeutics on treatment-resistant depression back when the neuro-focused biotech was working under the radar. Five years later, the Swiss pharma is helping itself to the rest of Cadent’s pipeline in a deal worth $210 million upfront but that could net the latter up to $770 million in total.
Sage Therapeutics is embarking on a new chapter in its development following its $1.5 billion alliance with Biogen last month, and that challenge will now be met by a new CEO.
Neurogene has raised $115 million in a second-round financing that will accelerate its plans to start clinical trials of a range of gene therapies for inherited neurological diseases, initially focusing on a form of Batten disease.
Michael Bruce, Ph.D., has worked for the likes of Pfizer and CRISPR Therapeutics, but now he’s the CEO of what he believes will be the future in medicine: Exo Therapeutics. The company raised $25 million (PDF) in series A funding to back a pipeline of drugs that bind their enzyme targets at their exosites. The goals are to create better medicines without harmful side effects and to hit targets that were previously considered undruggable.